Riskpilot← Back to searchSign inGet full accessUNUS Läkarkonsult AB
ABActiveOrg 5591847289Talluddsvägen 59Business and other management consultancy activities · NACE 7020Est. 20180 employees
Revenue 2025
SEK 85K
-14% vs 2024
EBITDA margin
47.9%
-44% vs 2024
Equity ratio
69.4%
Financial strength
Net profit 2025
SEK 28K
-46% vs 2024
| Revenue | SEK 85K | -14% |
| EBITDA | SEK 41K | -44% |
| Net profit | SEK 28K | -46% |
| Total assets | SEK 156K | +1% |
| Equity | SEK 108K | +35% |
| Employees | 0 | — |
Legal name
UNUS Läkarkonsult AB
Org number
5591847289
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
11 december 2018
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Mujezinovic, Sena
Company purpose
Bolaget ska bedriva konsult och föreläsningsverksamhet inom medicin hälsa och sjukvård samt förvaltning av kapital genom investering i aktier, värdepapper, fasta och lösa tillgångar.
Address
Talluddsvägen 59
Email
sena.muj@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 280 | 134 | 99 | 85 |
| Staff expenses | — | — | — | −0 | — |
| EBITDA | −50 | 258 | 111 | 73 | 41 |
| Depreciation & amort. | −0 | −6 | −6 | −6 | −6 |
| EBIT | −50 | 252 | 105 | 67 | 35 |
| Net financials | 1 | 1 | 2 | −1 | 0 |
| Profit before tax | 67 | 192 | 155 | 66 | 35 |
| Tax | −16 | −40 | −32 | −14 | −8 |
| Net profit | 51 | 152 | 123 | 52 | 28 |
| Item | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 920 | 439 | 313 | 155 | 156 |
| Equity | 292 | 256 | 183 | 81 | 108 |
| Long-term debt | 542 | 14 | 1 | 28 | 2 |
| Short-term debt | 85 | 107 | 113 | 31 | 31 |
| Total debt | 627 | 121 | 114 | 59 | 33 |
EBITDA margin
47.9%
This company
15.8%
Market median
+203% vs market
20222025
Equity ratio
69.4%
This company
38.2%
Market median
+82% vs market
20222025
Return on equity
25.7%
This company
18.4%
Market median
+40% vs market
20222025
Net profit margin
32.7%
This company
8.1%
Market median
+304% vs market
20222025
Asset turnover
0.55×
This company
1.12×
Market median
-51% vs market
20222025
Debt / equity
0.44×
This company
0.62×
Market median
+29% vs market
20222025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-05-01 – 2022-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Former (2) | ||
| Chairman | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of UNUS Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karin Ebba Sofia Ekenger | Chairman | 0 companies |
| Sena Mujezinovic | Chairman | 0 companies |
| Nurija Mujezinovic | Board of Directors | 0 companies |
| Karin Sofia Charlotte Ekenger | Deputy Board Member | 0 companies |
| Karl Gustaf Ekenger | Board of Directors | 0 companies |